Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.
Dr. Yael Cohen
Advertisement
Articles by Dr. Yael Cohen
Advertisement
Latest Updated Articles
Dr. Yael Cohen on Anti-Angiogenic Agent VB-111Published: October 29th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
The OncFive: Top Oncology Articles for the Week of 1/25
5